nVerses Capital LLC Invests $142,000 in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

nVerses Capital LLC purchased a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,900 shares of the company’s stock, valued at approximately $142,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NTLA. Goldman Sachs Group Inc. grew its holdings in shares of Intellia Therapeutics by 3.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 824,527 shares of the company’s stock valued at $25,140,000 after acquiring an additional 28,264 shares in the last quarter. Vanguard Group Inc. increased its position in Intellia Therapeutics by 1.9% in the 4th quarter. Vanguard Group Inc. now owns 8,347,449 shares of the company’s stock worth $254,514,000 after purchasing an additional 155,579 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Intellia Therapeutics by 209.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 10,561 shares of the company’s stock worth $322,000 after purchasing an additional 7,151 shares in the last quarter. Los Angeles Capital Management LLC lifted its holdings in shares of Intellia Therapeutics by 49.2% during the 1st quarter. Los Angeles Capital Management LLC now owns 17,449 shares of the company’s stock valued at $480,000 after buying an additional 5,754 shares during the last quarter. Finally, SteelPeak Wealth LLC bought a new stake in shares of Intellia Therapeutics in the 1st quarter valued at approximately $229,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock opened at $21.08 on Friday. The firm has a fifty day moving average price of $21.06 and a two-hundred day moving average price of $22.96. Intellia Therapeutics, Inc. has a fifty-two week low of $17.09 and a fifty-two week high of $34.87. The company has a market cap of $2.03 billion, a PE ratio of -3.93 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The company had revenue of $7.00 million during the quarter, compared to analyst estimates of $19.68 million. The firm’s quarterly revenue was down 48.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.40) earnings per share. Analysts expect that Intellia Therapeutics, Inc. will post -5.22 earnings per share for the current fiscal year.

Insider Activity

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of Intellia Therapeutics stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the sale, the chief accounting officer now owns 47,012 shares in the company, valued at $893,698.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have issued reports on NTLA. Canaccord Genuity Group reiterated a “buy” rating and issued a $73.00 target price on shares of Intellia Therapeutics in a research note on Thursday, June 27th. Stifel Nicolaus decreased their price objective on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday, September 11th. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 target price on shares of Intellia Therapeutics in a report on Monday, June 24th. Evercore ISI upgraded Intellia Therapeutics to a “strong-buy” rating in a research note on Friday, August 9th. Finally, JPMorgan Chase & Co. cut their price objective on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. One research analyst has rated the stock with a sell rating, four have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $61.77.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.